Aclaris Therapeutics Stock Price, Forecast & Analysis (NASDAQ:ACRS)

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Aclaris Therapeutics Inc (NASDAQ:ACRS) announced its earnings results on Thursday, November, 7th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.80. The biotechnology company had revenue of $0.98 million for the quarter, compared to analyst estimates of $5.87 million. Aclaris Therapeutics had a negative return on equity of 83.22% and a negative net margin of 1,165.39%. View Aclaris Therapeutics' Earnings History.

Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Aclaris Therapeutics.

5 analysts have issued 12 month price targets for Aclaris Therapeutics' shares. Their forecasts range from $5.00 to $13.00. On average, they anticipate Aclaris Therapeutics' share price to reach $9.00 in the next year. This suggests a possible upside of 376.2% from the stock's current price. View Analyst Price Targets for Aclaris Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aclaris Therapeutics.

Media coverage about ACRS stock has trended very negative recently, InfoTrie reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aclaris Therapeutics earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Aclaris Therapeutics.

Aclaris Therapeutics saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 4,260,000 shares, an increase of 62.0% from the September 30th total of 2,630,000 shares. Based on an average trading volume of 1,890,000 shares, the short-interest ratio is presently 2.3 days. Currently, 13.3% of the company's shares are short sold. View Aclaris Therapeutics' Current Options Chain.

Some companies that are related to Aclaris Therapeutics include Clovis Oncology (CLVS), AMAG Pharmaceuticals (AMAG), resTORbio (TORC), Corbus Pharmaceuticals (CRBP), Geron (GERN), Satsuma Pharmaceuticals (STSA), Theratechnologies (THERF), Urovant Sciences (UROV), Avid Bioservices (CDMO), AnaptysBio (ANAB), Protagonist Therapeutics (PTGX), GlycoMimetics (GLYC), CytomX Therapeutics (CTMX), Mallinckrodt (MNK) and Seres Therapeutics (MCRB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Ocular Therapeutix (OCUL), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Abeona Therapeutics (ABEO), BioDelivery Sciences International (BDSI) and Crispr Therapeutics (CRSP).

Aclaris Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Creative Planning (0.07%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, James E Flynn, Kamil Ali-Jackson, Neal Walker and Stephen A Tullman. View Institutional Ownership Trends for Aclaris Therapeutics.

ACRS stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Anand Mehra, Andrew Kenneth William Powell, Frank Ruffo, Neal Walker and Stephen A Tullman. View Insider Buying and Selling for Aclaris Therapeutics.

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACRS stock can currently be purchased for approximately $1.89.

Aclaris Therapeutics has a market capitalization of $78.23 million and generates $10.09 million in revenue each year. The biotechnology company earns $-132,740,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe.View Additional Information About Aclaris Therapeutics.

The official website for Aclaris Therapeutics is http://www.aclaristx.com/.

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]